AxoGen, Inc. provided revenue guidance for the fourth quarter of 2023. Fourth quarter revenue is expected to be approximately $42.7 million, which represents an 18% increase over the fourth-quarter of 2022 driven by solid performance across the product portfolio.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.8 USD | -2.86% | +8.45% | -0.44% |
May. 28 | Axogen, Inc. Announces the Opening of its Axogen Processing Center | CI |
May. 16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.44% | 299M | |
+7.01% | 217B | |
+11.01% | 190B | |
+19.20% | 143B | |
+30.79% | 111B | |
+1.48% | 64.59B | |
+13.95% | 52.36B | |
-0.16% | 48.45B | |
-6.20% | 38.03B | |
+0.91% | 35.6B |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- AxoGen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023